Charles J. Homcy
Known title: DirectorCIK: 0001192591
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pompe Disease Market Expected to Grow Through 2036. A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.
Transaction History
| BBIO | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 788 | $52K | 6/20/2026 | View on chart |
| MAZE | ▼ Sell | Gift | 7,422 | $0 | 5/4/2026 | View on chart |
| MAZE | ▼ Sell | Other | 1,489 | $0 | 11/19/2025 | View on chart |
| MAZE | ▼ Sell | Gift | 28,423 | $0 | 10/23/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 50,000 | $2.4M | 8/11/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 191,662 | $8.8M | 8/8/2025 | View on chart |
| BBIO | ▼ Sell | Open Market | 58,338 | $2.7M | 8/8/2025 | View on chart |
| BBIO | ▼ Sell | Gift | 20,000 | $0 | 6/27/2025 | View on chart |
| BBIO | ▲ Buy | Grant | 6,589 | $0 | 6/20/2025 | View on chart |
| MAZE | ▼ Sell | Other | 8,807 | — | 2/3/2025 | View on chart |
| MAZE | ▼ Sell | Other | 20,717 | — | 2/3/2025 | View on chart |
| MAZE | ▼ Sell | Other | 7,422 | — | 2/3/2025 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,760 | — | 2/16/2024 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,509 | $56K | 2/16/2024 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,760 | — | 11/16/2023 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,301 | $38K | 11/16/2023 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,760 | — | 8/16/2023 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,301 | $39K | 8/16/2023 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,759 | — | 5/16/2023 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,300 | $18K | 5/16/2023 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,760 | — | 2/16/2023 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,534 | $19K | 2/16/2023 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,760 | — | 11/16/2022 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,301 | $13K | 11/16/2022 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,760 | — | 8/16/2022 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,287 | $14K | 8/16/2022 | View on chart |
| BBIO | ▼ Sell | Tax Withholding | 1,541 | $10K | 5/16/2022 | View on chart |
| BBIO | ▲ Buy | Option Exercise | 3,759 | — | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success
BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success. BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.